(Q51047839)

27 March 2018

title

Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. (English)

1 reference

27 March 2018

main subject

patient

0 references

invasive aspergillosis

1 reference

3

1 reference

27 March 2018

Manuel Cuenca-Estrella

9

object named as

Manuel Cuenca-Estrella

1 reference

27 March 2018

author name string

Rafael F Duarte

1

1 reference

27 March 2018

Isabel Sánchez-Ortega

2

1 reference

27 March 2018

Montserrat Arnan

4

1 reference

27 March 2018

Beatriz Patiño

5

1 reference

27 March 2018

Alberto Fernández de Sevilla

6

1 reference

27 March 2018

Carlota Gudiol

7

1 reference

27 March 2018

Josefina Ayats

8

1 reference

27 March 2018

language of work or name

English

0 references

publication date

27 August 2014

1 reference

27 March 2018

Clinical Infectious Diseases

published in

1 reference

27 March 2018

volume

59

1 reference

27 March 2018

issue

12

1 reference

27 March 2018

page(s)

1696-1702

1 reference

27 March 2018

Aspergillosis case-fatality rate: systematic review of the literature

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Detection and investigation of invasive mould disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Intravenous PLASMA-LYTE as a major cause of false-positive results of platelia Aspergillus test for galactomannan detection in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Gluconate-containing intravenous solutions: another cause of false-positive galactomannan assay reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

The management of febrile neutropenia in the posaconazole era: a new challenge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Design issues in studies evaluating diagnostic tests for aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

Invasive aspergillosis complicating pandemic influenza A (H1N1) infection in severely immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU673

21 January 2018

Identifiers

DOI

10.1093/CID/CIU673

1 reference

27 March 2018

PubMed ID

25165088

1 reference

27 March 2018